Regeneron Ebit vs Research Development Analysis

REGN Stock

USD 883.20 7.48 0.84%

Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Ebit and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Ebit account and Research Development. At this time, the significance of the direction appears to have strong relationship.

The correlation between Regeneron Pharmaceuticals' Ebit and Research Development is 0.72. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Regeneron Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Regeneron Pharmaceuticals' Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Ebit

Research Development

Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 28th of April 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.97	1.0	0.94	-0.06	0.99	0.97	0.93	-0.24	0.96	0.98	0.15	0.95	0.32	-0.66	0.97	0.98	0.83	0.93	0.94	0.98	0.58	0.99	0.93	0.98	0.58
Total Current Liabilities	0.97		0.96	0.94	-0.03	0.95	0.99	0.84	-0.31	0.98	0.98	0.2	0.95	0.45	-0.66	0.99	0.99	0.73	0.96	0.88	0.99	0.65	0.97	0.83	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.93	-0.09	0.99	0.95	0.94	-0.25	0.95	0.96	0.13	0.92	0.28	-0.67	0.95	0.97	0.85	0.91	0.96	0.96	0.55	0.99	0.94	0.97	0.56
Property Plant And Equipment Net	0.94	0.94	0.93		-0.16	0.89	0.93	0.87	-0.15	0.91	0.94	0.31	0.96	0.37	-0.44	0.96	0.93	0.68	0.86	0.83	0.95	0.67	0.97	0.81	0.96	0.78
Net Debt	-0.06	-0.03	-0.09	-0.16		0.0	-0.1	-0.01	0.13	-0.14	-0.01	-0.17	0.08	-0.04	-0.49	0.02	-0.09	0.03	0.22	-0.16	-0.08	-0.04	-0.1	0.01	-0.06	-0.4
Retained Earnings	0.99	0.95	0.99	0.89	0.0		0.94	0.93	-0.26	0.95	0.96	0.05	0.91	0.27	-0.75	0.95	0.97	0.87	0.93	0.96	0.95	0.53	0.97	0.95	0.96	0.48
Cash	0.97	0.99	0.95	0.93	-0.1	0.94		0.82	-0.3	0.98	0.98	0.23	0.93	0.45	-0.62	0.98	0.99	0.71	0.95	0.88	0.98	0.63	0.95	0.82	0.97	0.54
Non Current Assets Total	0.93	0.84	0.94	0.87	-0.01	0.93	0.82		-0.07	0.8	0.86	0.07	0.88	0.14	-0.62	0.87	0.84	0.9	0.8	0.91	0.86	0.48	0.93	0.98	0.89	0.6
Non Currrent Assets Other	-0.24	-0.31	-0.25	-0.15	0.13	-0.26	-0.3	-0.07		-0.39	-0.2	-0.05	-0.06	-0.37	0.26	-0.19	-0.32	-0.4	-0.26	-0.26	-0.22	0.01	-0.22	-0.15	-0.23	-0.01
Cash And Short Term Investments	0.96	0.98	0.95	0.91	-0.14	0.95	0.98	0.8	-0.39		0.97	0.18	0.89	0.41	-0.63	0.95	0.99	0.73	0.92	0.91	0.97	0.58	0.95	0.82	0.95	0.5
Net Receivables	0.98	0.98	0.96	0.94	-0.01	0.96	0.98	0.86	-0.2	0.97		0.22	0.97	0.33	-0.65	0.99	0.99	0.71	0.96	0.89	0.98	0.62	0.97	0.85	0.97	0.56
Common Stock Shares Outstanding	0.15	0.2	0.13	0.31	-0.17	0.05	0.23	0.07	-0.05	0.18	0.22		0.28	0.27	0.37	0.24	0.19	-0.07	0.17	0.05	0.21	0.23	0.2	-0.02	0.16	0.47
Non Current Liabilities Total	0.95	0.95	0.92	0.96	0.08	0.91	0.93	0.88	-0.06	0.89	0.97	0.28		0.37	-0.59	0.99	0.93	0.67	0.94	0.81	0.96	0.69	0.95	0.83	0.96	0.65
Other Current Assets	0.32	0.45	0.28	0.37	-0.04	0.27	0.45	0.14	-0.37	0.41	0.33	0.27	0.37		-0.13	0.42	0.39	0.12	0.43	0.14	0.45	0.69	0.29	0.12	0.43	0.24
Other Stockholder Equity	-0.66	-0.66	-0.67	-0.44	-0.49	-0.75	-0.62	-0.62	0.26	-0.63	-0.65	0.37	-0.59	-0.13		-0.63	-0.65	-0.71	-0.76	-0.66	-0.61	-0.25	-0.6	-0.71	-0.63	0.11
Total Liab	0.97	0.99	0.95	0.96	0.02	0.95	0.98	0.87	-0.19	0.95	0.99	0.24	0.99	0.42	-0.63		0.97	0.71	0.96	0.86	0.99	0.68	0.97	0.84	0.98	0.61
Total Current Assets	0.98	0.99	0.97	0.93	-0.09	0.97	0.99	0.84	-0.32	0.99	0.99	0.19	0.93	0.39	-0.65	0.97		0.75	0.94	0.91	0.98	0.61	0.97	0.85	0.97	0.53
Intangible Assets	0.83	0.73	0.85	0.68	0.03	0.87	0.71	0.9	-0.4	0.73	0.71	-0.07	0.67	0.12	-0.71	0.71	0.75		0.71	0.87	0.72	0.28	0.81	0.94	0.77	0.37
Short Long Term Debt Total	0.93	0.96	0.91	0.86	0.22	0.93	0.95	0.8	-0.26	0.92	0.96	0.17	0.94	0.43	-0.76	0.96	0.94	0.71		0.81	0.94	0.61	0.91	0.81	0.94	0.4
Other Current Liab	0.94	0.88	0.96	0.83	-0.16	0.96	0.88	0.91	-0.26	0.91	0.89	0.05	0.81	0.14	-0.66	0.86	0.91	0.87	0.81		0.87	0.36	0.93	0.94	0.88	0.47
Accounts Payable	0.98	0.99	0.96	0.95	-0.08	0.95	0.98	0.86	-0.22	0.97	0.98	0.21	0.96	0.45	-0.61	0.99	0.98	0.72	0.94	0.87		0.73	0.97	0.84	0.99	0.59
Short Term Debt	0.58	0.65	0.55	0.67	-0.04	0.53	0.63	0.48	0.01	0.58	0.62	0.23	0.69	0.69	-0.25	0.68	0.61	0.28	0.61	0.36	0.73		0.57	0.41	0.67	0.49
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.1	0.97	0.95	0.93	-0.22	0.95	0.97	0.2	0.95	0.29	-0.6	0.97	0.97	0.81	0.91	0.93	0.97	0.57		0.91	0.97	0.65
Short Term Investments	0.93	0.83	0.94	0.81	0.01	0.95	0.82	0.98	-0.15	0.82	0.85	-0.02	0.83	0.12	-0.71	0.84	0.85	0.94	0.81	0.94	0.84	0.41	0.91		0.88	0.47
Inventory	0.98	0.98	0.97	0.96	-0.06	0.96	0.97	0.89	-0.23	0.95	0.97	0.16	0.96	0.43	-0.63	0.98	0.97	0.77	0.94	0.88	0.99	0.67	0.97	0.88		0.6
Other Liab	0.58	0.56	0.56	0.78	-0.4	0.48	0.54	0.6	-0.01	0.5	0.56	0.47	0.65	0.24	0.11	0.61	0.53	0.37	0.4	0.47	0.59	0.49	0.65	0.47	0.6

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Total Current Liabilities	1.8B	2.8B	3.5B	3.8B	3.4B	3.6B
Total Stockholder Equity	11.1B	11.0B	18.8B	22.7B	26.0B	27.3B
Property Plant And Equipment Net	2.9B	3.2B	3.5B	3.8B	4.1B	4.4B
Net Debt	(903.9M)	502M	(185.9M)	(404.5M)	(27.1M)	(28.5M)
Retained Earnings	7.4B	10.9B	19.0B	23.3B	27.3B	28.6B
Cash	1.6B	2.2B	2.9B	3.1B	2.7B	2.9B
Non Current Assets Total	4.2B	4.4B	4.9B	7.1B	13.6B	14.3B
Non Currrent Assets Other	531.8M	328.9M	555.2M	(4.7B)	444.1M	466.3M
Cash And Short Term Investments	6.5B	6.7B	12.5B	14.3B	10.8B	11.4B
Net Receivables	2.7B	4.1B	6.0B	5.3B	5.7B	6.0B
Common Stock Shares Outstanding	114.6M	115.1M	112.2M	113.5M	113.7M	75.4M
Liabilities And Stockholders Equity	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Non Current Liabilities Total	1.9B	3.3B	3.2B	2.7B	3.7B	3.9B
Other Current Assets	959.3M	1.2B	332.4M	933M	386.6M	203.9M
Other Stockholder Equity	3.7B	102.9M	(173.4M)	(404M)	(1.2B)	(1.1B)
Total Liab	3.7B	6.1B	6.7B	6.6B	7.1B	7.5B
Total Current Assets	10.6B	12.8B	20.5B	22.1B	19.5B	20.5B
Short Long Term Debt Total	713.9M	2.7B	2.7B	2.7B	2.7B	2.8B
Other Current Liab	781.1M	122.4M	1.7B	2.0B	2.4B	2.5B
Accounts Payable	418.1M	475.5M	564M	589.2M	606.6M	636.9M
Property Plant And Equipment Gross	2.9B	3.2B	4.9B	5.4B	6.1B	6.4B
Accumulated Other Comprehensive Income	21.1M	29.3M	(26.2M)	(238.8M)	(80.9M)	(76.9M)
Short Term Investments	1.6B	1.4B	2.8B	4.6B	8.1B	8.5B
Inventory	1.4B	1.9B	2.0B	2.4B	2.6B	2.7B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	913.3M	2.8B	555.2M	747.6M	859.7M	902.7M
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	591.7M	577.7M	442M	547.7M	458.9M	481.8M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B
Long Term Investments	3.3B	3.1B	6.8B	6.6B	5.4B	3.3B

Currently Active Assets on Macroaxis

F	Ford Motor
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GOOG	Alphabet Inc Class C
F	Ford Motor

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Content Syndication Quickly integrate customizable finance content to your own investment portal

Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.03)

Earnings Share

34.8

Revenue Per Share

122.935

Quarterly Revenue Growth

0.006

Return On Assets

0.0849

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

Regeneron Pharmaceuticals fundamental ratios Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Regeneron Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Current Liabilities

Short Long Term Debt Total	- 0.76	Other Stockholder Equity
Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Investments	- 0.71	Other Stockholder Equity
Intangible Assets	- 0.71	Other Stockholder Equity
Other Stockholder Equity	- 0.67	Total Stockholder Equity
Other Current Liab	- 0.66	Other Stockholder Equity